BioLineRx to Deliver Oral Presentation at ESMO

Dec 13, 2019

Abstract title: A Multi-Center Phase 2a Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)

 

Presentation No.: 91O

Lecture time: 11:00-11:30am CET

Location: Room C

Supporting Materials

Location

Geneva, Switzerland
Shape
Potential life-changing treatments are on the way

Each molecule in our development pipeline is carefully selected for its potential ability to improve upon the standard of care, delivering maximum value to patients